697762-60-0

Basic information

• Product Name: (S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate
• Synonyms: (S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate;7-Fluoro-1,4-dihydro-1-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-6-iodo-4-oxo-3-quinolinecarboxylic acid ethyl ester;3-Quinolinecarboxylic acid, 7-fluoro-1,4-dihydro-1-[(1S)-1-(hydroxyMethyl)-2-Methylpropyl]-6-iodo-4-oxo-, ethyl ester;(S)-Ethyl 7-fluoro-1-(1-hydroxy-3-methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxyla;(S)-Ethyl 7-fluoro-1-(1-hydroxy-3-methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carbox
• CAS NO: 697762-60-0
• Molecular Formula: C₁₇H₁₉FINO₄
• Molecular Weight: 447.2399332
• EINECS: -0
• Mol File: 697762-60-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 524.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.605±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.31±0.10(Predicted)
• CAS DataBase Reference: (S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate(697762-60-0)
• EPA Substance Registry System: (S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate(697762-60-0)

Safety Data

• Hazardous Substances Data: 697762-60-0(Hazardous Substances Data)

Usage

General Description

(S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate, also known as ethyl levofloxacin, is a chemical compound that belongs to the class of fluoroquinolone antibiotics. It is a semisynthetic derivative of the naturally occurring compound, ofloxacin. Ethyl levofloxacin is used to treat a variety of bacterial infections, including respiratory tract infections, urinary tract infections, and skin infections. Its mechanism of action involves inhibiting the bacterial DNA gyrase, which prevents the bacteria from replicating and ultimately leads to their death. Ethyl levofloxacin is typically administered orally and is well-absorbed into the bloodstream, allowing it to effectively target and eliminate the offending bacteria. However, it is important to note that this compound can have potential side effects and should be used with caution, particularly in individuals with a history of tendon disorders or other risk factors.

Upstream product

• 697762-39-3 ethyl 2-(2,4-difluoro-5-iodobenzoyl)-3-(dimethylamino)acrylate 
• 2026-48-4 (S)-valinol 
• 697762-59-7 C₁₇H₂₀F₂INO₄ 
• 1131640-54-4 (S,Z)-ethyl 2-(2,4-difluoro-5-iodobenzoyl)-3-(1-hydroxy-3-methylbutan-2-ylamino)acrylate 
• 1583-58-0 2,4-difluoro-benzoic acid 
• 161531-51-7 2,4-difluoro-5-iodobenzoic acid 
• 72-18-4 L-valine 

Downstream Products

• 1261283-91-3 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-[2-methyl-1-(tetrahydropyran-2-yloxymethyl)prop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 1261283-94-6 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-((S)-1-hydroxymethyl-2-methylprop-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid dicyclohexylamine salt 
• 1261283-95-7 1(S)-[1-(tert-butyldimethylsilanyloxymethyl)-2-methylprop-1-yl]-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261283-97-9 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-[2-methyl-1-(tetrahydropyran-2-yloxymethyl)prop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261283-99-1 1-(S)-[1-(tert-butyldimethylsilanyloxymethyl)-2-methylprop-1-yl]-6-(3-chloro-2-fluorobenzyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261284-01-8 6-(3-chloro-2-fluorobenzyl)-7-methoxy-1-[1-(S)-2-methyl-1-(tetrahydropyran-2-yloxymethyl)prop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 697762-63-3 C₂₄H₂₄ClF₂NO₄ 
• 697762-62-2 (S)-ethyl 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-(1-(methoxycarbonyloxy)-3-methylbutan-2-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 697762-66-6 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-[1-(S)-tert-butyldimethylsilyloxymethyl-2-methylprop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 697761-98-1 elvitegravir 
• 869893-92-5 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-((S)-1-hydroxymethyl-2-methylprop-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 870294-02-3 1-((2S)-1-tert-butyldimethylsilyloxy-3-methylbutan-2-yl)-7-fluoro-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 

Relevant articles and documents

AN IMPROVED PROCESS FOR THE PREPARATION OF ELVITEGRAVIR

The present invention relates to improved process for the preparation of elvitegravir (12), wherein the compound of formula (6) is protected with suitable protecting agents and further reacted with formula (9) in the presence of tetrakis(triphenylphosphin

Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors

Human immunodeficiency virus type 1 (HIV-1) integrase is a crucial target for antiretroviral drugs, and several keto - enol acid class (often referred to as diketo acid class) inhibitors have clinically exhibited-marked antiretroviral activity. Here, we show the synthesis and the detailed structure - activity relationship of the quinolone carboxylic acids as a novel monoketo acid class of integrase inhibitors. 6-(3-Chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3,3- dimethylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 51, which showed an IC50 of 5.8 nMin the strand transfer assay and an ED50 of 0.6 nMin the antiviral assay, and 6-(3-chloro-2-fluorobenzyl) -1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3- carboxylic acid 49, which had an IC50 of 7.2 nMand an ED50 of 0.9 nM, were the most potent compounds in this class. The monoketo acid 49 was much more potent at inhibiting integrasecatalyzed strand transfer processes than 3′-processing reactions, as is the case with the keto - enol acids. Elvitegravir 49 was chosen as a candidate for further studies and is currently in phase 3 clinical trials.

6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor

The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical composition, an anti-HIV